199 related articles for article (PubMed ID: 22507569)
1. Critical von Willebrand factor A1 domain residues influence type VI collagen binding.
Flood VH; Gill JC; Christopherson PA; Bellissimo DB; Friedman KD; Haberichter SL; Lentz SR; Montgomery RR
J Thromb Haemost; 2012 Jul; 10(7):1417-24. PubMed ID: 22507569
[TBL] [Abstract][Full Text] [Related]
2. Variability in platelet- and collagen-binding defects in type 2M von Willebrand disease.
Larsen DM; Haberichter SL; Gill JC; Shapiro AD; Flood VH
Haemophilia; 2013 Jul; 19(4):590-4. PubMed ID: 23496210
[TBL] [Abstract][Full Text] [Related]
3. Type 2M von Willebrand disease: F606I and I662F mutations in the glycoprotein Ib binding domain selectively impair ristocetin- but not botrocetin-mediated binding of von Willebrand factor to platelets.
Hillery CA; Mancuso DJ; Evan Sadler J; Ponder JW; Jozwiak MA; Christopherson PA; Cox Gill J; Paul Scott J; Montgomery RR
Blood; 1998 Mar; 91(5):1572-81. PubMed ID: 9473222
[TBL] [Abstract][Full Text] [Related]
4. Clinical and laboratory phenotype variability in type 2M von Willebrand disease.
Doruelo AL; Haberichter SL; Christopherson PA; Boggio LN; Gupta S; Lentz SR; Shapiro AD; Montgomery RR; Flood VH
J Thromb Haemost; 2017 Aug; 15(8):1559-1566. PubMed ID: 28544236
[TBL] [Abstract][Full Text] [Related]
5. Gain-of-function GPIb ELISA assay for VWF activity in the Zimmerman Program for the Molecular and Clinical Biology of VWD.
Flood VH; Gill JC; Morateck PA; Christopherson PA; Friedman KD; Haberichter SL; Hoffmann RG; Montgomery RR
Blood; 2011 Feb; 117(6):e67-74. PubMed ID: 21148813
[TBL] [Abstract][Full Text] [Related]
6. Comparison of type I, type III and type VI collagen binding assays in diagnosis of von Willebrand disease.
Flood VH; Gill JC; Christopherson PA; Wren JS; Friedman KD; Haberichter SL; Hoffmann RG; Montgomery RR
J Thromb Haemost; 2012 Jul; 10(7):1425-32. PubMed ID: 22507643
[TBL] [Abstract][Full Text] [Related]
7. Laboratory diagnosis and molecular classification of von Willebrand disease.
Gadisseur A; Hermans C; Berneman Z; Schroyens W; Deckmyn H; Michiels JJ
Acta Haematol; 2009; 121(2-3):71-84. PubMed ID: 19506352
[TBL] [Abstract][Full Text] [Related]
8. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
[TBL] [Abstract][Full Text] [Related]
9. Dominant von Willebrand disease type 2M and 2U are variable expressions of one distinct disease entity caused by loss-of-function mutations in the A1 domain of the von Willebrand factor gene.
Gadisseur A; van der Planken M; Schroyens W; Berneman Z; Michiels JJ
Acta Haematol; 2009; 121(2-3):145-53. PubMed ID: 19506361
[TBL] [Abstract][Full Text] [Related]
10. Molecular modeling of ligand and mutation sites of the type A domains of human von Willebrand factor and their relevance to von Willebrand's disease.
Jenkins PV; Pasi KJ; Perkins SJ
Blood; 1998 Mar; 91(6):2032-44. PubMed ID: 9490688
[TBL] [Abstract][Full Text] [Related]
11. A comparative evaluation of a new fully automated assay for von Willebrand factor collagen binding activity to an established method.
Stufano F; Baronciani L; Mane-Padros D; Cozzi G; Faraudo S; Peyvandi F
Haemophilia; 2018 Jan; 24(1):156-161. PubMed ID: 29168270
[TBL] [Abstract][Full Text] [Related]
12. Recombinant von Willebrand factor Arg578-->Gln. A type IIB von Willebrand disease mutation affects binding to glycoprotein Ib but not to collagen or heparin.
Randi AM; Jorieux S; Tuley EA; Mazurier C; Sadler JE
J Biol Chem; 1992 Oct; 267(29):21187-92. PubMed ID: 1400429
[TBL] [Abstract][Full Text] [Related]
13. Desmopressin therapy to assist the functional identification and characterisation of von Willebrand disease: differential utility from combining two (VWF:CB and VWF:RCo) von Willebrand factor activity assays?
Favaloro EJ; Thom J; Patterson D; Just S; Dixon T; Koutts J; Baccala M; Rowell J; Baker R
Thromb Res; 2009 Apr; 123(6):862-8. PubMed ID: 19064279
[TBL] [Abstract][Full Text] [Related]
14. Comparison of an automated chemiluminescent assay to a manual ELISA assay for determination of von Willebrand Factor collagen binding activity on VWD plasma patients previously diagnosed through molecular analysis of VWF.
Jousselme E; Jourdy Y; Rugeri L; Négrier C; Nougier C
Int J Lab Hematol; 2018 Feb; 40(1):77-83. PubMed ID: 28980759
[TBL] [Abstract][Full Text] [Related]
15. Type 2M:Milwaukee-1 von Willebrand disease: an in-frame deletion in the Cys509-Cys695 loop of the von Willebrand factor A1 domain causes deficient binding of von Willebrand factor to platelets.
Mancuso DJ; Kroner PA; Christopherson PA; Vokac EA; Gill JC; Montgomery RR
Blood; 1996 Oct; 88(7):2559-68. PubMed ID: 8839848
[TBL] [Abstract][Full Text] [Related]
16. The interaction of von Willebrand factor-A1 domain with collagen: mutation G1324S (type 2M von Willebrand disease) impairs the conformational change in A1 domain induced by collagen.
Morales LD; Martin C; Cruz MA
J Thromb Haemost; 2006 Feb; 4(2):417-25. PubMed ID: 16420575
[TBL] [Abstract][Full Text] [Related]
17. Dominant von Willebrand disease type 2A groups I and II due to missense mutations in the A2 domain of the von Willebrand factor gene: diagnosis and management.
Michiels JJ; van Vliet HH
Acta Haematol; 2009; 121(2-3):154-66. PubMed ID: 19506362
[TBL] [Abstract][Full Text] [Related]
18. Defective collagen binding and increased bleeding in a murine model of von Willebrand disease affecting collagen IV binding.
Slobodianuk TL; Kochelek C; Foeckler J; Kalloway S; Weiler H; Flood VH
J Thromb Haemost; 2019 Jan; 17(1):63-71. PubMed ID: 30565388
[TBL] [Abstract][Full Text] [Related]
19. High resolution multimer analysis and the PFA-100 platelet function analyser can detect von Willebrand disease type 2A without a pathological ratio of ristocetin cofactor activity and von Willebrand antigen level.
Weiss DR; Strasser EF; Ringwald J; Zimmermann R; Eckstein R
Clin Lab; 2012; 58(11-12):1203-9. PubMed ID: 23289190
[TBL] [Abstract][Full Text] [Related]
20. Performance and clinical utility of a commercial von Willebrand factor collagen binding assay for laboratory diagnosis of von Willebrand disease.
Popov J; Zhukov O; Ruden S; Zeschmann T; Sferruzza A; Sahud M
Clin Chem; 2006 Oct; 52(10):1965-7. PubMed ID: 16887898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
